Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1Dermatologic 1

Conditions

Glioblastoma 405Brain Neoplasms 163Glioma 159Gliosarcoma 131Astrocytoma 115Central Nervous System Neoplasms 110Melanoma 75Oligodendroglioma 74Neuroblastoma 44Neoplasms 33Medulloblastoma 33Neoplasm Metastasis 29Recurrence 28Ependymoma 26Sarcoma 23Sarcoma, Ewing 22Rhabdomyosarcoma 18Small Cell Lung Carcinoma 16Lymphoma 16Carcinoma, Non-Small-Cell Lung 16Diffuse Intrinsic Pontine Glioma 15Lung Neoplasms 14Breast Neoplasms 14Ovarian Neoplasms 13Neuroendocrine Tumors 13Choroid Plexus Neoplasms 13Optic Nerve Glioma 11Neuroectodermal Tumors, Primitive 11Spinal Cord Neoplasms 10Rhabdoid Tumor 10

Interventions

relacorilant 3pembrolizumab 3cabozantinib 2Mifepristone 2Corlux 2veliparib 1tariquidar 1olaparib 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1Temozolomide 1Specimen Handling 1Pharmacogenomic Variants 1Pharmacogenomic Testing 1Osilodrostat 1Nivolumab 1Mesna 1Magnetic Resonance Spectroscopy 1Gefitinib 1Floxuridine 1Dexamethasone 1Cyclophosphamide 1Capecitabine 1Axitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Adrenal Cortex Neoplasms × Temozolomide × Clear all
NCT02831179 2017-09-28

Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor

Vanderbilt-Ingram Cancer Center

Phase 1 Withdrawn
DermatologicEndocrineGastrointestinalNET

Non functioning pancreatic endocrine tumor, Adrenal Cortex Neoplasms, Carcinoid Tumor, Vipoma, Glucagonoma, Insulinoma, Pheochromocytoma, Somatostatinoma, Zollinger-Ellison Syndrome, Carcinoma, Merkel Cell, Carcinoma, Medullary, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 1, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡